165 related articles for article (PubMed ID: 26553291)
21. Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.
Wang Y; Chen Y; Geng H; Qi C; Liu Y; Yue D
Tumour Biol; 2015 Sep; 36(9):7159-66. PubMed ID: 25877750
[TBL] [Abstract][Full Text] [Related]
22. Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.
Karlowee V; Amatya VJ; Takayasu T; Takano M; Yonezawa U; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
Pathobiology; 2019; 86(2-3):152-161. PubMed ID: 31096221
[TBL] [Abstract][Full Text] [Related]
23. Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature.
Xu B; Abourbih S; Sircar K; Kassouf W; Mansure JJ; Aprikian A; Tanguay S; Brimo F
Arch Pathol Lab Med; 2013 Oct; 137(10):1326-36. PubMed ID: 24079759
[TBL] [Abstract][Full Text] [Related]
24. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas.
Venneti S; Garimella MT; Sullivan LM; Martinez D; Huse JT; Heguy A; Santi M; Thompson CB; Judkins AR
Brain Pathol; 2013 Sep; 23(5):558-64. PubMed ID: 23414300
[TBL] [Abstract][Full Text] [Related]
26. EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study.
Schweiger T; Hegedüs B; Nikolowsky C; Hegedüs Z; Szirtes I; Mair R; Birner P; Döme B; Lang G; Klepetko W; Ankersmit HJ; Hoetzenecker K
Ann Surg Oncol; 2014 Mar; 21(3):946-54. PubMed ID: 24281417
[TBL] [Abstract][Full Text] [Related]
27. The noncanonical role of EZH2 in cancer.
Huang J; Gou H; Yao J; Yi K; Jin Z; Matsuoka M; Zhao T
Cancer Sci; 2021 Apr; 112(4):1376-1382. PubMed ID: 33615636
[TBL] [Abstract][Full Text] [Related]
28. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
29. Genetic polymorphisms in the polycomb group gene EZH2 and the risk of lung cancer.
Yoon KA; Gil HJ; Han J; Park J; Lee JS
J Thorac Oncol; 2010 Jan; 5(1):10-6. PubMed ID: 19901851
[TBL] [Abstract][Full Text] [Related]
30. [Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases].
Gao J; Sun ZW; Li YY; Shen L
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):579-83. PubMed ID: 23157823
[TBL] [Abstract][Full Text] [Related]
31. H3K27me3 may be associated with Oct4 and Sox2 in mouse preimplantation embryos.
Wu FR; Zhang Y; Ding B; Lei XH; Huang JC; Wang CH; Liu Y; Wang R; Li WY
Genet Mol Res; 2014 Dec; 13(4):10121-9. PubMed ID: 25501223
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma.
Adackapara CA; Sholl LM; Barletta JA; Hornick JL
Histopathology; 2013 Aug; 63(2):187-93. PubMed ID: 23763264
[TBL] [Abstract][Full Text] [Related]
34. Comparative Study of Mutations in Single Nucleotide Polymorphism Loci of
Galanopoulos M; Papanikolaou IS; Zografos E; Viazis N; Papatheodoridis G; Karamanolis D; Marinos E; Mantzaris GJ; Gazouli M
Anticancer Res; 2017 Feb; 37(2):651-657. PubMed ID: 28179313
[TBL] [Abstract][Full Text] [Related]
35. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
[TBL] [Abstract][Full Text] [Related]
36. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
37. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
[TBL] [Abstract][Full Text] [Related]
38. Association between EZH2 polymorphisms and colorectal cancer risk in Han Chinese population.
Wang J; Ma ZB; Li K; Guo GH
Med Oncol; 2014 Mar; 31(3):874. PubMed ID: 24488618
[TBL] [Abstract][Full Text] [Related]
39. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia.
Chen J; Li J; Han Q; Sun Z; Wang J; Wang S; Zhao RC
Exp Biol Med (Maywood); 2012 Sep; 237(9):1110-6. PubMed ID: 22956625
[TBL] [Abstract][Full Text] [Related]
40. Expression of a constitutively active prolactin receptor causes histone trimethylation of the p53 gene in breast cancer.
Tan D; Tang P; Huang J; Zhang J; Zhou W; Walker AM
Chin Med J (Engl); 2014; 127(6):1077-83. PubMed ID: 24622438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]